Bayer anticipated that their experimental blood clot drug might generate more than 5 billion euros ($5.4 billion) in peak annual sales. The next-generation blood thinner is one of four novel medicine options with a combined peak sales potential of more than 12 billion euros, according to Bayer. This includes a brighter prognosis for the kidney medication Kerendia, with potential yearly sales now expected to exceed 3 billion euros.
Related post: Researchers turn white blood cells into microrobots for targeted drug delivery
Bayer has targeted a unique class of pharmaceuticals known as factor XI inhibitors, which have also interested Novartis and Blackstone. Bayer’s trial plan is more advanced than those of its rivals, and a request for regulatory clearance is on the cards in early 2026.
English